Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial

Kristin L Wickens, Christine A Barthow, Rinki Murphy, Peter R Abels, Robyn M Maude, Peter R Stone, Edwin A Mitchell, Thorsten V Stanley, Gordon L Purdie, Janice M Kang, Fiona E Hood, Judy L Rowden, Phillipa K Barnes, Penny F Fitzharris, Julian Crane, Kristin L Wickens, Christine A Barthow, Rinki Murphy, Peter R Abels, Robyn M Maude, Peter R Stone, Edwin A Mitchell, Thorsten V Stanley, Gordon L Purdie, Janice M Kang, Fiona E Hood, Judy L Rowden, Phillipa K Barnes, Penny F Fitzharris, Julian Crane

Abstract

The study aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 (HN001) can reduce the prevalence of gestational diabetes mellitus (GDM). A double-blind, randomised, placebo-controlled parallel trial was conducted in New Zealand (NZ) (Wellington and Auckland). Pregnant women with a personal or partner history of atopic disease were randomised at 14-16 weeks' gestation to receive HN001 (6×109 colony-forming units) (n 212) or placebo (n 211) daily. GDM at 24-30 weeks was assessed using the definition of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (fasting plasma glucose ≥5·1 mmol/l, or 1 h post 75 g glucose level at ≥10 mmol/l or at 2 h ≥8·5 mmol/l) and NZ definition (fasting plasma glucose ≥5·5 mmol/l or 2 h post 75 g glucose at ≥9 mmol/l). All analyses were intention-to-treat. A total of 184 (87 %) women took HN001 and 189 (90 %) women took placebo. There was a trend towards lower relative rates (RR) of GDM (IADPSG definition) in the HN001 group, 0·59 (95 % CI 0·32, 1·08) (P=0·08). HN001 was associated with lower rates of GDM in women aged ≥35 years (RR 0·31; 95 % CI 0·12, 0·81, P=0·009) and women with a history of GDM (RR 0·00; 95 % CI 0·00, 0·66, P=0·004). These rates did not differ significantly from those of women without these characteristics. Using the NZ definition, GDM prevalence was significantly lower in the HN001 group, 2·1 % (95 % CI 0·6, 5·2), v. 6·5 % (95 % CI 3·5, 10·9) in the placebo group (P=0·03). HN001 supplementation from 14 to 16 weeks' gestation may reduce GDM prevalence, particularly among older women and those with previous GDM.

Keywords: Lactobacillus rhamnosus HN001; Fonterra Fonterra Co-operative Group Ltd; GDM gestational diabetes mellitus; GTT glucose tolerance test; HN001 Lactobacillus rhamnosus HN001; IADPSG International Association of Diabetes and Pregnancy Study Group; NZ New Zealand; RR relative rate; Gestational diabetes mellitus; Probiotics; Randomised controlled trials.

Figures

Fig. 1
Fig. 1
Status of study participants through the trial. GDM, gestational diabetes mellitus; NZ, New Zealand; GTT, glucose tolerance test.
Fig. 2
Fig. 2
Lactobacillus rhamnosus HN001 (HN001) associations with gestational diabetes mellitus (GDM) stratified by (a) age ≥35 v. <35 years, (b) BMI≥30 v. <30 kg/m2, (c) history of GDM and (d) systemic antibiotic use since enrolment.

References

    1. Ministry of Health (2014) Screening, Diagnosis and Management of Gestational Diabetes in New Zealand: A Clinical Practice Guideline. Wellington: Ministry of Health.
    1. American College of Obstetricians and Gynecologists Committee (2013) ACOG Committee opinion number 549: Obesity in pregnancy. Obstet Gynecol 121, 213–217.
    1. Kim SY, England L, Wilson HG, et al. (2010) Percentage of gestational diabetes mellitus attributable to overweight and obesity. Am J Public Health 100, 1047–1052.
    1. Ben-Haroush A, Yogev Y & Hod M (2004) Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med 21, 103–113.
    1. Kim C, Newton KM & Knopp RH (2002) Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care 25, 1862–1868.
    1. International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) International Association of Diabetes and Pregnancy Study Groups Recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33, 676–682.
    1. Coustan DR, Lower LP, Metzger BE, et al. (2010) The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 202, 654.e651–e656.
    1. Food and Agriculture Organization/World Health Organization (2002) Guidelines for the Evaluation of Probiotics in Food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London: FAO/WHO.
    1. Gomes AC, Beuno AA, de Souza RGM, et al. (2014) Gut microbiota, probiotics and diabetes. Nutr J 13, 60.
    1. Zhang Q, Yucheng W & Xiaoqiang F (2016) Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicina 52, 28–34.
    1. Thomas LV, Ockhuizen T & Suzuki K (2014) Exploring the influence of the gut microbiota and probiotics on health: a symposium report. Br J Nutr 112, S1–S18.
    1. Luoto R, Laitinen K, Nermes M, et al. (2010) Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr 103, 1792–1799.
    1. Barthow C, Wickens K, Stanley T, et al. (2016) The Probiotics in Pregnancy Study (PiP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy. BMC Pregnancy Childbirth 16, 133.
    1. Wickens K, Black PN, Stanley TV, et al. (2008) A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 122, 788–794.
    1. Zhou JS, Pillidge CJ, Gopal PK, et al. (2005) Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. Int J Food Microbiol 98, 211–217.
    1. Laitinen K, Poussa T, Isolauri E, et al. (2009) Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomized controlled trial. Br J Nutr 101, 1679–1687.
    1. Lindsay KL, Kennelly M, Culliton M, et al. (2014) Probotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). Am J Clin Nutr 99, 1432–1439.
    1. Lindsay KL, Brennan L, Kennelly MA, et al. (2015) Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized trial. Am J Obstet Gynecol 212, 496.e1–e11.
    1. Francino MP (2016) Antibiotics and the human gut microbiome: dysbiosis and accumulation of resistances. Front Microbiol 6, 1543.
    1. Koren O, Goodrich JK, Tyler CC, et al. (2012) Host remodelling of the gut microbiome and metabolic changes during pregnancy. Cell 150, 470–480.
    1. Ministry of Health (2014) Guidance for Healthy Weight Gain During Pregnancy. Wellington: Ministry of Health.
    1. Fattah C, Farah N, Barry SC, et al. (2010) Maternal weight and body composition in the first trimester of pregnancy. Acta Obstet Gynecol Scand 89, 952–955.
    1. Prescott SL (2013) Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases. J Allergy Clin Immunol 131, 23–30.
    1. Fisher JE, Smith RS, Lagrandeur R, et al. (1997) Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol 90, 880–883.
    1. Braatvedt GD, Cundy T, Crooke M, et al. (2012) Understanding the new HbA1c units for the diagnosis of type 2 diabetes. N Z Med J 125, 70–80.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir